REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that Norman Michael Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer, will participate in a panel discussion on immuno-oncology being held during the 2017 BIO International Conference on Thursday, June 22, 2017, from 10:15 a.m. - 11:15 a.m. PT in San Diego, CA.
The panel, titled “Immune-Oncology Drugs: Ready for First Line Therapy?”, will take place in Room 7A in the San Diego Convention Center.
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® technology profiles a patient’s immune response at the single-cell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.